Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2251 • ACR Convergence 2022
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Matthew Baker¹, Yuhan Liu¹, Rong Lu¹, Janice Lin¹, Jason Melehani¹ and William Robinson², ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
Abstract Number: 0062 • ACR Convergence 2022
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
Justin Levinson¹, Jonathan Katz², Yi Chen³, W. Ryan Powell⁴, Andrea Gilmore-Bykovskyi⁵, Amy J. Kind⁶ and Christie Bartels⁷, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, ²University of Wisconsin Hospitals and Clinics, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Department of Biostatistics and Informatics, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ⁵University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…
Abstract Number: 0121 • ACR Convergence 2022
Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines
Megan Thomas¹, Cheryl Barnabe², Tessa Kleissen², Diane Lacaille³, Glen Hazlewood², Nejat Hassen⁴, Richard Henry⁵, Kelly English⁶, Michael Kuluva⁷, Aurore Fifi-Mah² and Nicole Johnson², ¹University of British Columbia, Vancouver, BC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Arthritis Research Canada, RICHMOND, BC, Canada, ⁵McGill University, Montréal, QC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁷Creaky Joints, Vancouver, BC, Canada
Background/Purpose: Guidelines may unintentionally introduce inequities in care through recommendations that do not reflect the realities of healthcare access and quality for persons who are…
Abstract Number: 0243 • ACR Convergence 2022
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka¹, Eisuke Inoue², Kotaro Watanabe³, Mai Abe³, Eri Sugano³, Kumiko Saka³, Moeko Ochiai³, Rei Yamaguchi³, Katsunori Ikari⁴ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Research Administration Center, Showa University, Shinagawa-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Japan, ⁴Department of Orthopedic Surgery, Tokyo Women’s Medial University School of Medicine, Shinjuku, Japan
Background/Purpose: The number of elderly patients with rheumatoid arthritis (RA) has been constantly increasing. As of December 2021, 50.3% of the patients with RA who…
Abstract Number: 0259 • ACR Convergence 2022
Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
Ju Yeon Kim¹, Kichul Shin², Eun Bong Lee¹ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: This study aims to evaluate the impact of comorbidities on disease activity and functional disability in patients with RA treated with biological disease-modifying anti-rheumatic…
Abstract Number: 0276 • ACR Convergence 2022
Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study
James Galloway¹, Karen Bevers², Patrick Verschueren³, Roberto Felice Caporali⁴, Susana Romero Yuste⁵, Jérôme Avouac⁶, Emilia Gvozdenovic⁷, Kristina Harris⁷, Monia Zignani⁷ and Gerd Burmester⁸, ¹King's College London, London, United Kingdom, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³University Hospital Leuven, Leuven, Belgium, ⁴University of Milan, Milano, Italy, ⁵Complexo Hospitalario Universitario, Pontevedra, Spain, ⁶University of Paris, Paris, France, ⁷Galapagos NV, Mechelen, Belgium, ⁸Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a preferential Janus kinase 1 inhibitor, approved in Europe for the treatment of RA and ulcerative colitis. A phase 4 European…
Abstract Number: 0293 • ACR Convergence 2022
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁶ and Roy Fleischmann⁷, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, ³Aurora Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target…
Abstract Number: 0311 • ACR Convergence 2022
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects
Ajay Aggarwal¹, David Burt², Laura Connelly², Joseph Monahan² and Jessea Lu², ¹Aclaris Therapeutics, Wellesley, MA, ²Aclaris Therapeutics, Inc., Wayne, PA
Background/Purpose: Zunsemetinib is an orally available potent and selective small molecule inhibitor of the p38α MAPK/MK2 signaling axis. Aclaris Therapeutics, Inc. is developing zunsemetinib for…
Abstract Number: 0533 • ACR Convergence 2022
Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity
Timothy Wilson¹, Jacob Welch², Marie Feser², Elizabeth Bemis², Claudia Lugo², Gary S. Firestein³, Thomas F. Bumol⁴, Jill Norris⁵, V. Michael Holers⁶, Kevin D Deane⁷ and Kristen Demoruelle², ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California, San Diego, San Diego, CA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Aurora, CO, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO
Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…
Abstract Number: 0591 • ACR Convergence 2022
Deficiency of FUN14 Domain-Containing Protein 1-Mediated Mitophagy in Fibroblast-like Synoviocytes Causes Aggressive Behaviors Leading to Joint Destruction in Rheumatoid Arthritis
Qian Zhang¹, Tao Wu¹, Jian-da Ma², Yao-Wei Zou¹, Xue-Pei Zhang¹, Hu-Wei Zheng¹, Jun Jing¹, Yao-yao Zou³, Le-feng Chen¹ and Lie Dai², ¹Sun Yat-Sen University, Guangzhou, China, ²Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ³Guangdong People's Hospital, Guangzhou, China
Background/Purpose: Synovial fibroblast-like synoviocytes (FLSs) actively participate in the pathogenesis of rheumatoid arthritis (RA). FUN14 domain-containing protein 1 (FUNDC1), a novel mitophagy receptor, plays critical…
Abstract Number: 0607 • ACR Convergence 2022
Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness
Camilla Machado¹, Hyeonjeong Lee², Sho Sendo³, Narayanan Perumal⁴, Wei Wang⁵, David Boyle⁵ and Gary S. Firestein⁶, ¹UCSD, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University California, San Diego (UCSD), La Jolla, CA, ⁴Eli Lilly Company, San Diego, ⁵University of California San Diego, San Diego, ⁶University of California, San Diego, San Diego, CA
Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) display an aggressive behavior. Previous studies have implicated cadherins in FLS function in this phenotype, which are type…
Abstract Number: 0625 • ACR Convergence 2022
Distinct Effects of JAK Inhibitor and TNF Inhibitors on Circulating B Cell Phenotypes in Rheumatoid Arthritis Patients
Mehreen Elahee¹, Kathryne Marks¹, Ifeoluwakiisi Adejoorin¹, Lin Chen¹, Derrick Todd¹, Jonathan Coblyn¹, Elena Massarotti¹, Susan Ritter¹, Daniel Solomon¹, Michael Weinblatt² and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Multiple DMARDs are used to treat rheumatoid arthritis (RA) yet, there are currently few tools to assess if DMARD treatment influences pathologic immune cell…
Abstract Number: 0757 • ACR Convergence 2022
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
Pankti Reid¹, Sabina Sandigursky², Maria A. Lopez-Olivo³, Juhee Song⁴, Houssein Safa⁵, Samuel Cytryn⁶, Maryam Buni⁷, Anna Pavlick⁸, Michelle Krogsgaard, PhD⁹, Osama Abu-Shawer¹⁰, Mehmet Altan¹¹, Jeffrey Weber¹², Maria Suarez-Almazor¹³, Adi Diab¹⁴ and Noha Abdel-Wahab¹⁴, ¹University of Chicago Medical Center, Chicago, IL, ²NYU Langone Health, New York, NY, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁶Memorial Sloan Kettering Cancer Center, New York, NY, ⁷MD Anderson Cancer Center, Bellaire, TX, ⁸Medical Oncology, Weill Cornell Medical Center, New York, NY, ⁹Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, ¹⁰Cleveland Clinic Foundation, Cleveland, OH, ¹¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ¹²NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, NY, ¹³MD Anderson Cancer Center, Houston, TX, ¹⁴UT MD Anderson Cancer Center, Houston, TX
Background/Purpose: Treatment with a combination of immune checkpoint inhibitors (ICI) has promising outcomes in many tumor types but carries higher adverse event risk than ICI…
Abstract Number: 0819 • ACR Convergence 2022
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
Anchal Sabharwal¹, Yuanqing Liu¹, Yazmin Rustomji¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Connective tissue diseases (CTDs) are a category of autoimmune disease in which interstitial lung disease (ILD) is a common pulmonary manifestation. Due to the…
Abstract Number: 0897 • ACR Convergence 2022
Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis
Gregory McDermott¹, Kumar Dahal¹, Su-Jin Moon², Thany Seyok¹, Dana Weisenfeld¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Despite the efficacy of modern biologic and small molecule medications, a significant proportion of RA patients have inadequate response to multiple therapies. These patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].